SRA Wins $100 Million Contract with Department of Defense
August 10 2010 - 4:01PM
Business Wire
SRA International, Inc. (NYSE: SRX), a leading provider of
technology and strategic consulting services and solutions to
government organizations and commercial clients, today announced
that the Department of Defense (DoD) awarded the company a
re-compete contract to support the receipt and scientific review of
research grant applications for DoD’s Congressionally Directed
Medical Research Programs (CDMRP). The contract has a potential
total dollar value of $100 million over five years, if all options
are exercised.
SRA has provided a vast range of services supporting scientific
and technical merit review of the thousands of research grant
applications received by the U.S. Army Medical Research and
Materiel Command’s (USAMRMC) CDMRP. Research initiatives supported
by SRA have included breast, prostate and ovarian cancers; chronic
myelogenous leukemia; osteoporosis; neurofibromatosis; tuberous
sclerosis complex; autism spectrum disorder, amyotrophic lateral
sclerosis, post traumatic stress disorder, traumatic brain injury,
prion diseases; and initiatives related to the health and readiness
of military personnel.
“CDMRP plays an important role in supporting disease-specific
research, and in addressing the issues faced by our military
members and their families. SRA fully shares this mission and we
are proud that CDMRP will allow us to continue this partnership,”
said SRA Health Programs Vice President Paul Nedzbala. “By
leveraging our scientific expertise, information technology and
administrative support, SRA has been able to provide an unsurpassed
level of service to CDMRP. Our team is focused on CDMRP’s mission
as we make meaningful contributions to advances in important areas
of biomedical research.”
A centerpiece of SRA’s support for CDMRP (and other scientific
peer review clients) is its proprietary Program and Peer Review
Management Information System (P2RMIS®) application, which supports
the scientific review process, including online application
evaluation and scoring, meeting and travel support, document
management and information reporting. P2RMIS also houses a database
of thousands of scientific professionals who have served on peer
review panels and/or who are available to serve.
CDMRP holds a highly respected position in the research
community for its emphasis on investment strategies that fill
unique gaps and seek innovative ideas with the capacity to effect
transformational change in the treatment of targeted diseases and
conditions. CDMRP is rare among federal grant makers because of its
emphasis on meaningful consumer engagement, disease-specific
approach, pursuit of innovative research and two-tiered review
process that results in funding decisions based on technical merit
and programmatic relevance.
About SRA International, Inc.
SRA and its subsidiaries are dedicated to solving complex
problems of global significance for government organizations and
commercial clients serving the national security, civil government
and global health markets. Founded in 1978, the company and its
subsidiaries have expertise in such areas as air surveillance and
air traffic management; contract research organization (CRO)
services; cyber security; disaster response planning; enterprise
resource planning; environmental strategies; IT systems,
infrastructure and managed services; logistics; public health
preparedness; public safety; strategic management consulting;
systems engineering; and wireless integration.
SRA and its subsidiaries employ more than 7,000 employees
serving clients from its headquarters in Fairfax, Va., and offices
around the world. For additional information on SRA, please visit
www.sra.com.
Any statements in this press release about future expectations,
plans, and prospects for SRA, including statements about the
estimated value of the contract and work to be performed, and other
statements containing the words “estimates,” “believes,”
“anticipates,” “plans,” “expects,” “will,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements. In addition, the forward-looking statements included in
this press release represent our views as of August 10, 2010. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to August 10,
2010.
Sra (NYSE:SRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sra (NYSE:SRX)
Historical Stock Chart
From Aug 2023 to Aug 2024